Literature DB >> 6492693

Negative inotropic effects of aldosterone antagonists in isolated human and guinea-pig ventricular heart muscle.

A Mügge, W Schmitz, H Scholz.   

Abstract

The effects of K+-canrenoate (Aldactone pro inj.) and its metabolite canrenone on isometric force of contraction were measured in isolated guinea-pig and human papillary muscle preparations driven electrically at a frequency of 1 Hz. In guinea-pig hearts both substances exerted a concentration-dependent negative inotropic effect; the IC50 of K+-canrenoate and canrenone were 129 +/- 22 mumol l-1 (n = 5) and 85 +/- 11 mumol l-1 (n = 12), respectively. At the maximally tested concentration canrenone (250 mumol l-1) and K+-canrenoate (1,000 mumol l-1) reduced force of contraction by 68 +/- 4% (n = 12) and 83 +/- 3% (n = 5), respectively. The negative inotropic effects of canrenone and K+-canrenoate were not affected by 10 mumol l-1 atropine. The negative inotropic effect of canrenone was also not affected by 14 mumol l-1 aldosterone, but canrenone (10 mumol l-1 diminished the maximal positive inotropic effect of dihydro-ouabain from 554 +/- 75% (n = 4) to 269 +/- 39% (n = 4) of the predrug value. In human heart muscles K+-canrenoate and canrenone also exerted a concentration-dependent negative inotropic effect. K+-canrenoate (1,000 mumol l-1) and canrenone (250 mumol l-1) reduced force of contraction by 57 +/- 7% (n = 8) and 67 +/- 2% (n = 6), respectively. A positive inotropic effect of both substances was never observed. It is concluded that the improvement of cardiac performance after application of aldosterone antagonists observed in patients cannot be explained by a direct effect on the heart. K+-canrenoate and canrenone are devoid of any direct cardiotonic action. Instead, K+-canrenoate and canrenone have direct negative inotropic effects at high concentrations.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6492693     DOI: 10.1007/bf01725704

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  19 in total

1.  [Extrarenal effects of potassium-canrenoate. Haemodynamic investigations during neuroleptanalgesia in cardiosurgical patients (author's transl)].

Authors:  S Piepenbrock; G Hempelmann; S Schwarz; H Oelert
Journal:  Anaesthesist       Date:  1979-04       Impact factor: 1.041

2.  Effect of potassium canrenoate on cardiac functions and (Na + + K + )-activated ATPase.

Authors:  S I Baskin; T Akera; C R Puckett; S L Brody; T M Brody
Journal:  Proc Soc Exp Biol Med       Date:  1973-06

3.  Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.

Authors:  W Sadée; M Dagcioglu; R Schröder
Journal:  J Pharmacol Exp Ther       Date:  1973-06       Impact factor: 4.030

4.  Failure of potassium canrenoate to alter experimentally induced digitalis arrhythmias.

Authors:  B R Lucchesi; N R Haley
Journal:  Eur J Pharmacol       Date:  1973-06       Impact factor: 4.432

5.  [Myocardial aspects of aldactone effect].

Authors:  B E Strauer
Journal:  Verh Dtsch Ges Inn Med       Date:  1972

6.  Evidence for a positive inotropic effect of aldadiene (-K, -Na) on the isolated ventricular myocardium.

Authors:  B E Strauer; H Avenhaus; M Nose
Journal:  Klin Wochenschr       Date:  1972-04-01

7.  Systolic time intervals during spironolactone treatment of digitalized and non-digitalized patients with ischaemic heart disease.

Authors:  S Waldorff; J Berning; J Buch; E Steiness
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Canrenoate--a spironolactone metabolite. Acute cardiac effects in digitalized patients.

Authors:  S Waldorff; J Buch
Journal:  Eur J Cardiol       Date:  1979-08

9.  Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium-activated adenosine triphosphatase.

Authors:  P Finotti; P Palatini
Journal:  J Pharmacol Exp Ther       Date:  1981-06       Impact factor: 4.030

10.  [Aldactone (spironolactone, canrenoate-K) in the treatment of chronic cor pulmonale].

Authors:  U Hüttemann; K P Schüren
Journal:  Dtsch Med Wochenschr       Date:  1972-10-13       Impact factor: 0.628

View more
  2 in total

1.  The negative inotropic action of canrenone is mediated by L-type calcium current blockade and reduced intracellular calcium transients.

Authors:  A R Costa; L B Torres; E Medei; R A Ricardo; J P França; S Smaili; J H M Nascimento; M E M Oshiro; J W M Bassani; A T Ferreira; P J F Tucci
Journal:  Br J Pharmacol       Date:  2009-08-06       Impact factor: 8.739

2.  The interaction of canrenone with the Na+,K+ pump in human red blood cells.

Authors:  R P Garay; J Diez; C Nazaret; G Dagher; J P Abitbol
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-05       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.